Insurers doing just fine on fair access, says drug price watchdog

2 December 2021

The US Institute for Clinical and Economic Review (ICER), best known for its cost-effectiveness analyses of innovative drugs and biologics, has published a report on payers’ fair access to medicines.

The ICER, which is criticized by drugmakers for being biased towards the insurance industry, found that payers are generally doing a fine job at providing fair access to their products.

The results are based on the Bostonian group’s own “exploratory analysis,” designed to compare levels of access to a list of 28 drugs it regards as being fairly priced.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK